PFF Teal = 0+160+175 MAIN COLORS PFF Green = 120+162+47 Light Green = 193+216+47 Red = 242+102+73 HIGHLIGHT COLORS Light Grey = 220+220+210 Dark Grey =

Slides:



Advertisements
Similar presentations
UCSF School of Medicine OCME Program Frequently Asked Questions Faculty Disclosure and Resolution of Conflict of Interest.
Advertisements

Mycology review.
Caring for Patients with COPD: Guidelines for Diagnosis and Management M. Elizabeth Knauft, MD MS September 20, 2007.
BY DR.Khaled Helmy Chest Specialist Al Mahmora Chest Hospital Ministry of Health - Egypt COPD SCOPE ON.
Managing Conflicts of Interest © ACCME.
University of Calgary - Undergraduate Medicine RESPIRATORY COURSE OCCUPATIONAL LUNG DISEASE: CASE PRESENTATIONS Kenneth Corbet MD FRCPC Community Health.
F 1+7/12 yrs CC: cough and mild cyanosis Diffuse pulmonary opacity.
Dyspnea and Rash Andres Quiceno, MD Rheumatology PHD.
2013 Joint KMS and MSMA CME Provider Conference. The Provider describes that its CME Committee sets the topics and educational goals of its CME activities.
YOUR DISCLOSURE STATEMENT Of particular note this year is a rule change by ACCME regarding standards for commercial support, specifically: Standard 4.3:
INTERSTITIAL LUNG DISEASE
Idiopathic Pulmonary Fibrosis (IPF) How we could do better Dr. D. K. Pillai Wednesday, 13 th August 2014 Medical Update Group at UoM.
IDIOPATHIC PULMONARY FIBROSIS
THE DIAGNOSIS OF IPF Steven A. Sahn, MD
Hypersensitivity Pneumonitis
DIAGNOSIS of AUTOIMMUNE DISEASES Assos. Prof. Gülderen Yanıkkaya Demirel MD, PhD Yeditepe University School of Medicine Immunology Department, Medical.
Standards for Commercial Support: Standards to Ensure Independence in CME Activities SM Case Studies.
AUTOANTIBODIES IN RHEUMATOLOGY G. Cooke VTS Trainee.
Jointly Sponsored by The Warren Alpert Medical School of Brown University and the New England Regional Chapter of the Society of Adolescent Health and.
ACCREDITATION CRITERIA CONFLICT OF INTEREST CONTENT INTEGRITY.
Esam H. Alhamad, M.D Assistant Professor of Medicine Consultant Pulmonary & Critical Care Medicine.
Pulmonary Fibrosis Foundation Summit 2015
PFF Teal = MAIN COLORS PFF Green = Light Green = Red = HIGHLIGHT COLORS Light Grey = Dark Grey =
PFF Teal = MAIN COLORS PFF Green = Light Green = Red = HIGHLIGHT COLORS Light Grey = Dark Grey =
PFF Teal = MAIN COLORS PFF Green = Light Green = Red = HIGHLIGHT COLORS Light Grey = Dark Grey =
PFF Teal = MAIN COLORS PFF Green = Light Green = Red = HIGHLIGHT COLORS Light Grey = Dark Grey =
PFF Teal = MAIN COLORS PFF Green = Light Green = Red = HIGHLIGHT COLORS Light Grey = Dark Grey =
Speaker Disclosure Explanation
PFF Teal = MAIN COLORS PFF Green = Light Green = Red = HIGHLIGHT COLORS Light Grey = Dark Grey =
PFF Teal = MAIN COLORS PFF Green = Light Green = Red = HIGHLIGHT COLORS Light Grey = Dark Grey =
PFF Teal = MAIN COLORS PFF Green = Light Green = Red = HIGHLIGHT COLORS Light Grey = Dark Grey =
PFF Teal = MAIN COLORS PFF Green = Light Green = Red = HIGHLIGHT COLORS Light Grey = Dark Grey =
History : 52-year-old male presented with a left testicular mass. An initial chest radiograph was performed, followed by a CT. Question : What are the.
PFF Teal = MAIN COLORS PFF Green = Light Green = Red = HIGHLIGHT COLORS Light Grey = Dark Grey =
Hepatitis. Hepatitis * Definition: Hepatitis is necro-inflammatory liver disease characterized by the presence of inflammatory cells in in the portal.
David E. Kleiner, M.D., Ph.D Staff Surgical Pathologist, Laboratory of Pathology, NCI (1992-Present) Hepatic Pathologist –Collaborations with Dr. Jay Hoofnagle.
PFF Teal = MAIN COLORS PFF Green = Light Green = Red = HIGHLIGHT COLORS Light Grey = Dark Grey =
PFF Teal = MAIN COLORS PFF Green = Light Green = Red = HIGHLIGHT COLORS Light Grey = Dark Grey =
PFF Teal = MAIN COLORS PFF Green = Light Green = Red = HIGHLIGHT COLORS Light Grey = Dark Grey =
PFF Teal = MAIN COLORS PFF Green = Light Green = Red = HIGHLIGHT COLORS Light Grey = Dark Grey =
PFF Teal = MAIN COLORS PFF Green = Light Green = Red = HIGHLIGHT COLORS Light Grey = Dark Grey =
Should it be viewed as a single entity? Hypersensitivity pneumonitis Should it be viewed as a single entity? Venerino Poletti versus Athol Wells.
Clinical Case 11 th February th Course of Diffuse Parenchymal Lung Diseases.
Clinical Tools for the Primary Care Physician. Objectives Raise the clinical index of suspicion for ILD in patients presenting with the hallmark signs.
Date of download: 9/17/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Demystifying Idiopathic Interstitial Pneumonia Arch.
Emerging Approaches to Treatment of IPF Gregory P. Cosgrove, MD Associate Professor, Pulmonary Division Assistant Director, Interstitial Lung Disease Program.
Rheumatology Mastery in Ankylosing Spondylitis
YOUR DISCLOSURE STATEMENT
Smoking related interstitial fibrosis – a new entity
Pff disease education webinar series
Neurological Clinicopathologic Case Presentation
Contemporary Paradigms for Anticoagulant Reversal
David L. Bell, MD, MPH Assistant Clinical Professor of Pediatrics
Subjects characteristics
Heart Failure Management
HOW LOW SHOULD YOU TARGET LDL-C?
Demystifying Idiopathic Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis: Current Concepts
831_ePAT CARE: Patient case Dr. Molina Dr
Disclosure Relevant relationships with commercial entities:
Respiratory MCNs - Interstitial lung diseases
Name: Age: Sex: Presenting History Symptom progression Current status:
Can Mobile Technology Improve Outcomes?
Copyright © 2016 by ASCP.
Chronic Obstructive Pulmonary Disease: An Evidence-Based Approach to Treatment With a Focus on Anticholinergic Bronchodilation  Nicholas J. Gross, MD,
Disclosure of Faculty Conflict of Interest
3º Curso de Doenças Pulmonares Difusas – FMUP/HSJ
How is pulmonary fibrosis diagnosed and monitored?
THE TITLE OF MY TALK John Doe, M.D. Professor Department of Neurology
Diagnostic algorithm for idiopathic pulmonary fibrosis (IPF).
Presentation transcript:

PFF Teal = MAIN COLORS PFF Green = Light Green = Red = HIGHLIGHT COLORS Light Grey = Dark Grey = Black = CASE PRESENTATION II ANDREW YOUN, MD, FRCPC CLINICAL CARE: MULTIDISCIPLINARY DIAGNOSIS NOVEMBER 14, 2015

PFF Teal = MAIN COLORS PFF Green = Light Green = Red = HIGHLIGHT COLORS Light Grey = Dark Grey = Black = FACULTY DISCLOSURE In accordance with the Accreditation Council for Continuing Medical Education, The France Foundation requires that all program faculty, content developers, CME approval committee, and medical writers in a position to control the content of this activity are expected to disclose any or not significant financial interest or other relationship with any proprietary entity producing health care goods or services, with the exemption of nonprofit or governmental organizations and non-health care related companies. Our goal is to ensure that there is no compromise of the ethical relationship that exists between those in a position to control the content of the activity and those attending the activity and their respective professional duties. All CME Educational Activities sponsored by The France Foundation are reviewed by our faculty CME committee to ensure a balanced and evidence-based presentation. Any potential conflict of interest among program faculty has been identified and resolved according to ACCME guidelines. Andrew Youn, MD, FRCPC, has no relevant disclosures. ©2015 Pulmonary Fibrosis Foundation. All rights reserved.2

Clinical Care: Multidisciplinary Diagnosis Case III Andrew Youn, MD FRCPC Clinical Fellow Interstitial Lung Disease University of Toronto

Case History Meds: 1.Prednisone 5mg PO OD 2.Imuran 50mg PO OD 3.Plaquenil 200mg PO OD 4.Atorvastatin 10mg PO QHS SHx: Life-time non-smoker Non-drinker No illicit drug use FHx: Negative for ILD, CTD ID: 69F PMHx: 1.SLE. Dx’ed 1974, clinically stable. 2.GERD 3.Hypercholesterolemia 4.Thrombocytopenia

Case History HPI: SLE initially diagnosed in 1974 – Clinically stable for past 20 years Beginning in early 2014, rheumatologist noticed presence of mild bibasilar crackles Referred to ILD clinic at TGH for assessment on April 2015 – MRC dyspnea class 2, intermittent dry cough Exposure History: No pneumotoxic drugs (including gold, MTX) No occupational exposures Significant for having parrot x 30 years, budgies x 5 years

Case History Autoimmune Serology (Oct 2014) – ANA 1:640 homogeneous – Anti-SSB (La) 1.2 AI units – Anti-chromatin >8.0 AI units – Anti-ribosomal P 1.0 AI units – Negative Anti-SSA (Ro), Anti- Sm, Anti –SmRNP, Anti-RNP, Anti-SCl70, Anti-Jo-1, ACA – Anti-dsDNA 28 U/mL – C g/L, C g/L Pulmonary Function Test (April 2015)

What’s going on? The main DDx at this point was… CTD-ILD versus Hypersensitivity Pneumonitis

HRCT (Nov 2014)

HRCT (Feb 2015)

VATS lung biopsy (RUL, RML) on May 2015

Pathology

Official pathology report: – “Mild to moderate mixed interstitial chronic inflammatory infiltrates associated with occasional non-necrotizing granulomas and scattered foamy macrophages. The inflammation and granulomas tend to show a centrilobular predominance…The lung parenchymal architecture is preserved without evidence of remodeling.”

Summary 69F with long history of SLE, with clear exposure to HP antigens Definite diagnosis of HP (secondary to avian antigens) After removal of birds (to humane society), significant improvement in symptoms No other changes to management

Thank you Dr. Charlene Fell Dr. Shane Shapera Dr. David Hwang Dr. Jeffrey Tanguay